BioLargo begins testing source waters from prospective clients with its PFAS treatment technology
Westminster, CA – July 26, 2021 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and full-service environmental engineering company, announced that two potential clients (a major municipality in Southern California and a federal government agency) are sending it PFAS-contaminated water samples to be treated by BioLargo’s AEC water treatment system. This is the first step of BioLargo’s multi-phased commercial approach: (1) off-site treatment of client supplied water, (2) on-site pilot treatment at client location, and (3) full-scale operation. In this first step, BioLargo receives contaminated water from the client, evaluates it for operational optimization, treats the water removing the PFAS chemicals, and then has an independent laboratory analyze the treated water to confirm the PFAS has been removed to client specifications. In essence, it is a “proof of concept” phase to give the client confidence in moving to the next phase. Assuming a successful first phase, these agencies have asked for proposals for on-site piloting to confirm treatment success at a larger scale at the client location. Once piloting is complete, BioLargo would offer customized commercial-scale systems to each client.
Randall Moore, President of BioLargo Engineering, Science
& Technologies said, “By treating client water through our in-house AEC
system, we can optimize it for the unique characteristics of the water from each
source and confirm for the client that our system removes PFAS to the levels
that meet their particular regulatory requirements.”
The AEC (Aqueous Electrostatic Concentrator) is BioLargo’s
proprietary water treatment technology specifically designed to remove PFAS
(per- and polyfluoroalkyl substances), a group of man-made “forever” chemicals of
great emerging regulatory concern (learn more about PFAS on our blog post here:
https://bit.ly/3jmIyWN), from water and
soil.
On July 21, 2021, the House of Representatives passed the “PFAS Action
Act of 2021”. Introduced by a bipartisan coalition in March 2021, the
proposed legislation would establish a national drinking water standard for
select PFAS chemicals under the Safe Drinking Water Act, designate them as
hazardous chemicals (allowing the EPA to clean up contaminated sites and creating
stricter rules for handling them under CERCLA), limit industrial discharges
under the Clean Water Act, and provide $200 million annually to assist water
utilities and treatment facilities to remove PFAS chemicals from their water. The
bill would also restrict incineration of PFAS-containing wastes under the Clean
Air Act, which could significantly limit the use of the most common treatment
strategy: carbon filtration followed by carbon incineration.
BioLargo’s AEC technology has been proven to remove more
than 99% of PFAS from contaminated water, and, compared with carbon filtration
systems, generates about one tenth the PFAS-laden waste and costs less to operate.
Decreased waste minimizes the environmental and regulatory burdens associated
with water treatment.
Tonya Chandler, Director of Strategic Marketing and Business
Development at BioLargo, said “With
the passing of the PFAS Action Act of 2021 by the House of Representatives,
PFAS regulations are just around the corner. BioLargo is in a perfect position
to launch its revolutionary PFAS removal system into the market. The AEC
produces significantly less waste than traditional systems making it a superior
solution in this regulatory environment.”
Learn more about BioLargo’s AEC treatment through its
engineering division at www.biolargoengineering.com/biolargo-aec
Contact Tonya Chandler for more information or to schedule treatment
consultation at tonya.chandler@biolargo.com.
About BioLargo, Inc.
BioLargo,
Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform
technologies to solve challenging environmental problems like PFAS
contamination, advanced water and wastewater treatment, industrial odor and VOC
control, air quality control, and infection control. With over 13 years of
extensive R&D, BioLargo holds a wide array of issued patents, maintains a
robust pipeline of products, and provides full-service environmental engineering. Our
peer-reviewed scientific approach allows us to invent or acquire novel
technologies and develop them to maturity through our operating subsidiaries.
With a keen emphasis on collaborations with academic, municipal, and commercial
organizations and associations, BioLargo has proven itself with over 80 awarded
grants and numerous pilot projects. We monetize through direct sales, recurring
service contracts, licensing agreements, strategic joint venture formation
and/or the sale of the IP. See our website at www.BioLargo.com.
Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863
Safe Harbor Act
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements include without limitation those
about BioLargo’s (the “Company”) expectations regarding anticipated plans for
future operations. These statements involve risks and uncertainties, and actual
results may differ materially from any future results expressed or implied by
the forward-looking statements. Risks and uncertainties include without
limitation: the effect of the COVID-19 pandemic on the Company’s business,
results of operations, financial condition, and stock price; the effect of
regional economic conditions on the Company’s business, including effects on
purchasing decisions by consumers and businesses; the ability of the Company to
compete in markets that are highly competitive and subject to rapid
technological change; the ability of the Company to manage frequent
introductions and transitions of products and services, including delivering to
the marketplace, and stimulating customer demand for, new products, services,
and technological innovations on a timely basis; the dependency of the Company
on the performance of distributors of the Company’s products. More information
on these risks and other potential factors that could affect the Company’s
business and financial results is included in the Company’s filings with the
SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis
of Financial Condition and Results of Operations” sections of the Company’s
most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent
filings. The Company assumes no obligation to update any forward-looking
statements or information, which speak as of their respective dates.
No comments:
Post a Comment